Clearance Summary
FastPack IP Sex Hormone Binding Globulin Immunoassay received FDA 510(k) clearance under submission number K182521, sponsored by Qualigen, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Clinical Chemistry review panel. The statutory decision date of record is 2019-01-29.
- Submission: K182521
- Applicant / Sponsor: Qualigen, Inc.
- Clearance pathway: Traditional
- Review panel: Clinical Chemistry
- Device class: Class I
- Regulation citation: 21 CFR 862.1680
- Decision date: 2019-01-29
Classification & Regulation
This clearance is catalogued under FDA product code CDZ and 21 CFR 862.1680, within the Clinical Chemistry review panel as a Class I device.